Collagen, the most prevalent structural protein in the human body, is essential for maintaining the integrity of joints. With advancing age, endogenous collagen synthesis progressively declines, contributing to the deterioration of joint structures, including reduced cartilage resilience, increased stiffness, and decreased mobility. Additionally, extrinsic factors, particularly repetitive joint stress and inflammatory processes, exacerbate collagen degradation within joint tissues.

In this context, oral supplementation with collagen peptides has emerged as a promising approach to counteract age-related and stress-induced joint degeneration.

The present article reviews the mechanistic rationale and preclinical evidence underlying the use of low-molecular-weight MÖV® x3Peptide Collagen developed by Weishardt, with a focus on their enhanced bioactivity.

The efficacy of collagen supplementation is primarily attributed to its content of low-molecular-weight peptides, particularly dipeptides and tripeptides, which demonstrate superior absorption and bioavailability. These peptides efficiently cross the intestinal barrier and enter systemic circulation, thereby facilitating targeted delivery to tissues such as joints. Within joint tissues, di- and tripeptides modulate cellular signaling pathways involved in the maintenance and regeneration of muscles, ligaments, tendons, cartilage, and bone. MÖV® x3Peptide is a bovine collagen characterized by a high concentration of di- and tripeptides (minimum 25%) and a lower average molecular weight compared to standard collagen peptides. This profile is achieved through a proprietary enzymatic hydrolysis process designed to optimize gastrointestinal absorption and enhance bioefficacy.

Joint function depends on the integrity of healthy articular cartilage, where chondrocytes play a pivotal role in sustaining structural stability through the synthesis and regulation of the collagen-rich extracellular matrix, which accounts for approximately 70% of cartilage composition. This integrity is strongly influenced by the ability of chondrocytes to modulate key mediators such as matrix metalloproteinases (MMPs). Among them, MMP-1 and MMP-13 are of particular importance, as their overexpression is closely linked to cartilage degradation in joint disorders.

The bioactivity of MÖV® x3Peptide was assessed by evaluating its effects on inflamed human chondrocytes in comparison with a standard bovine collagen reference (“Bovine Collagen X”, average molecular weight: 2000 Da). MMP expression levels in chondrocytes were measured following stimulation with either MÖV® x3Peptide or Bovine Collagen X at equivalent doses, as well as with MÖV® x3Peptide at one-third of the standard dose..

Stimulation with MÖV® x3Peptide led to a more substantial reduction in MMPs production, underscoring its superior efficacy. Remarkably, even at a lower dose, MÖV® x3Peptide outperformed the full dose of standard collagen. These findings underscore the pivotal role of MÖV® x3Peptide in enhancing the functional potential of collagen peptides.

MÖV® x3Peptide has also demonstrated effectiveness in companion animals, with excellent product acceptance. In a panel study involving 40 dogs, supplementation with MÖV® x3Peptide led to measurable improvements in joint pain within 6 weeks, accompanied by enhanced mobility. These outcomes highlight its broad applicability and strong performance across species.

MÖV® x3Peptide represents a new generation of collagen supplementation, characterized by a high concentration of bioactive di- and tripeptides. Its superior efficacy distinguishes it from standard collagen peptides and paves the way for the development of low-dose nutritional supplements with enhanced activity. Moreover, its demonstrated effectiveness in companion animals underscores its broad translational potential, positioning MÖV® x3Peptide as a versatile and innovative solution in the field of collagen supplementation.

WEISHARDT INTERNATIONAL
www.weishardt.com